Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
Five steps to CER success?: Three contributors to high-level discussions on comparative effectiveness research (CER) propose a five-step process toward developing a national CER program in a New England Journal of Medicine article published online Feb. 17. Jordan VanLare of the Department of Health and Human Services, Patrick Conway, executive director of the Federal Coordinating Council for CER, and Harold Cox, co-chair of the Institute of Medicine's Committee on CER Prioritization, suggest first establishing an overall funding strategy. The program should focus on a coordinated portfolio of research on priority topics, infrastructure enhancement, and translation and adoption. Next, it should create an initial list of priority topics and evaluate current knowledge on each, and, with outside input, choose research methods that will fill the evidence gaps for specific topics. Finally, the program should strive for a "balanced portfolio of high-impact research topics" and publicly report on its progress. Last summer, IOM submitted a report to Congress with 100 recommended priorities for federally funded CER (1"The Gray Sheet" July 6, 2009)
You may also be interested in...
Vertebroplasty Shows No More Benefit Than Sham Procedures In Trials
The first two blinded, randomized, placebo-controlled trials of vertebroplasty treatment for spinal fractures suggest that the procedure may have no lasting benefit, researchers report in the Aug. 6 New England Journal of Medicine
Institute Of Medicine Sets Top 100 Comparative Effectiveness Priorities
A June 30 Institute of Medicine 1report to Congress includes dozens of surgical- and device-related topics among a list of 100 recommended priorities for federally-funded comparative effectiveness research
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.